COVID-19 vaccines have been around for half a year, what have we learned so far?

This article is brought to you thanks to the collaboration of The European Sting with the World Economic Forum.

Author: John Letzing, Digital Editor, Strategic Intelligence, World Economic Forum

• Signs are so far encouraging in terms protection, safety, and saving lives.

• More than 2 billion doses have been administered globally.

• However, many people may not receive a single dose for at least another year.

One thing we know for sure: they don’t make you magnetic.

Those fortunate enough to receive the first available doses of COVID-19 vaccines have been serving as test subjects. Roughly half a year into this global experiment, what have we learned so far?

A pair of studies published last month suggested that vaccination can indeed provide a plausible path out of the pandemic, and by early June 2 billion doses had been administered worldwide since the first went to a woman in the UK the previous December.

COVID-19 vaccines had saved nearly an estimated 12,000 lives in England alone by last month, China has been vaccinating a population the size of Romania every day, and San Francisco, where nearly 70% of residents had been fully vaccinated as of early this month, is the first US city on the verge of herd immunity.

Globally, daily confirmed cases and deaths have been trending downward since April. So far, it’s safe to say, vaccines seem to be working well.

One real-world study published in March of people in Denmark prioritized for the Pfizer-BioNTech vaccine found it was 90% effective among healthcare workers, and 64% effective among residents of long-term care facilities with a median age of 84.

However, troubling variants like “Delta” in India, the UK, and the US have raised questions about their potential resilience to vaccines. A study published in the UK last month found that two doses of the Pfizer-BioNTech vaccine were 88% effective against symptomatic disease from Delta, though epidemiologists have warned that variants could ultimately render current vaccines ineffective in a year or less.

Potential side effects have been another concern. Rare occurrences of a blood-clotting syndrome have been linked to the Oxford-AstraZeneca and Johnson & Johnson vaccines, but experts say the benefits still outweigh the risks.

A fact overshadowing any good news about vaccines is that much of the world hasn’t yet been able to receive any doses at all. One analysis suggested that more than 85 countries, mostly in Africa, won’t have widespread COVID-19 vaccine access before 2023.

Below is a visualization of COVID-19 vaccination doses administered per 100 people between January and May of this year – each country turns white as data becomes available, then progressively darker blue as the number of administered doses increases.

According to the Centers for Disease Control in the US, fully vaccinated people should be able to resume activities without masks (except where mandated), and travel without testing or quarantining. Still, experts caution against gatherings of multiple households without precautions if some people there are unvaccinated.

A study published in April in the UK found that receiving a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines notably reduced the odds of infecting other household members, and another published last month found that the viral load was significantly diminished for people in Israel infected a couple of weeks past their first dose of Pfizer-BioNTech – making them less infectious to others.

Yet another study published by the US CDC last month showed that two doses of the Pfizer-BioNTech and Moderna vaccines reduced the risk of healthcare workers getting sick with COVID-19 by 94%.

Researchers are still gathering what scant evidence has accumulated so far on how long protection lasts after vaccination. The role of booster shots may start to become clearer in September, when results from a study in England providing boosters to people at least 10 weeks past their second vaccine dose are anticipated.

Unfortunately, a significant number of people remain reluctant to be vaccinated. In the US, recent poll results showed that 24% of adults said they don’t plan to be vaccinated – and 78% of those people were unlikely to reconsider.

Another report published last month found that even though just 64% of adults in the US said they’d gotten at least one vaccine dose or intended to, general enthusiasm about getting vaccinated was reaching a plateau.

For more context, here are links to further reading from the World Economic Forum’s Strategic Intelligence platform:

• How about a “universal” coronavirus vaccine to prevent the next pandemic? This piece delves into an effort to develop next-generation immunization to protect against known and unknown varieties. (Scientific American)

• One proven means to overcome vaccine hesitancy in a remote area of India has been to address concerns in Korku, an endangered language still spoken by at least 600,000 indigenous people. (IndiaSpend)

• People with disabilities haven’t been prioritized for vaccination, according to this opinion piece, even though they account for a disproportionate number of adverse outcomes including a mortality rate in the UK roughly twice that of the general population. (Devex)

• When a respected medical historian agreed to appear in a documentary about the pandemic, according to this report, she assumed it would be a straightforward piece of journalism – not anti-vaccination propaganda aimed at Black Americans. (Kaiser Health News)

• Unvaccinated children seem to be reaping the benefits of mass COVID-19 vaccination programmes, but according to this analysis experts disagree on whether these children may now be a potential hotbed for the emergence of new variants. (Nature)

• Vaccine myth buster: this paper focuses on myths fuelling vaccine hesitancy, and examines the most prevalent related topics including formaldehyde, aluminium, mercury, autism, and misconceptions regarding COVID-19 vaccines. (Frontiers)

• The global vaccination effort has been nothing short of extraordinary, according to this analysis, but the overwhelming majority of the world’s population remains unprotected. (Project Syndicate)

On the Strategic Intelligence platform, you can find feeds of expert analysis related to Vaccination, COVID-19 and hundreds of additional topics. You’ll need to register to view.